Workflow
Drug Manufacturers
icon
Search documents
X @Bloomberg
Bloomberg· 2025-09-17 06:34
Indian firms are gearing up to supply the basic ingredient that goes in making copies of Novo's weight-loss drugs https://t.co/htCapzPlkP ...
X @Bloomberg
Bloomberg· 2025-09-16 23:18
British drugmaker GSK Plc pledged to invest $30 billion in the US over the next five years, making the announcement as President Donald Trump arrives in the UK for a highly anticipated state visit https://t.co/HkyI54iRBe ...
X @Bloomberg
Bloomberg· 2025-09-16 17:07
US regulators issued a flurry of letters calling out pharmaceutical companies for allegedly misleading ads https://t.co/nDUos3cssQ ...
X @Bloomberg
Bloomberg· 2025-09-12 10:04
The struggles of Novo Nordisk has economists wondering whether Denmark's economy relies too heavily on the success of the company -- and its blockbuster weight loss drugs https://t.co/oobJqrCUvI ...
X @Bloomberg
Bloomberg· 2025-09-05 17:44
Market Dynamics - Shares of Eli Lilly and Novo Nordisk experienced a decline [1] - US regulators established a "green list" of foreign manufacturers producing raw materials for GLP-1 drugs [1] Regulatory Landscape - The "green list" allows compounding pharmacies to create copies of blockbuster GLP-1 drugs [1]
X @Bloomberg
Bloomberg· 2025-09-03 16:30
Goldman Sachs and KKR are among lenders providing around €1.4 billion of one of the most expensive types of debt to back CapVest Partners’ acquisition of a majority stake in German drugmaker Stada Arzneimittel AG https://t.co/RXjEOE2v7s ...
X @Bloomberg
Bloomberg· 2025-08-21 08:08
Demand for Novo’s weight-loss blockbuster Wegovy is getting a boost in the UK from an unexpected corner: arch-rival Eli Lilly https://t.co/GLKpjCQVSC ...
Leerink's Risinger on Eli Lilly downgrade: Triggered by disappointing obesity pill results
CNBC Television· 2025-08-07 18:59
All right, let's get an analyst take on this with this Eli Liy story and the future of the obesity drug market really hanging in the balance right now. David Risinger is a senior research analyst at Link Partners. He just, by the way, downgraded Eli Liy just today to a market perform from a prior outperform.He also lowered his price target from $944 down to $715. Two very significant and notable moves. David, uh, we just heard Angelica's report.It basically sets you up to take us into some more detail about ...
X @Bloomberg
Bloomberg· 2025-07-29 15:18
A widening gulf between the stock performances of Novo and its main competitor Lilly has drawn comparison with two of the world’s largest luxury-goods makers https://t.co/laJDl6f0bK ...